Retina Institute Japan, Fukuoka, develops an iPS-based cure for age-related macular degeneration. The IP is on exclusive license from RIKEN, and Dainippon Sumitomo Pharma buys for 1.500 million Yen (12 million €) on an exclusive third party agreement. Retina Institute Japan was founded only in February, 2011.

Dainippon Sumitomo Pharma press release, March 28, 2013